Reversal of direct oral anticoagulants

References

• WeitzJIAnticoagulation therapy in 2015: where we are and where we are goingJ Thromb Thrombolysis201539326427225698404
   PubMedGoogle Scholar
• Gómez-OutesASuárez-GeaMLCalvo-RojasGDiscovery of anticoagulant drugs: a historical perspectiveCurr Drug Discov Technol2012928310421838662
   PubMedGoogle Scholar
• Chai-AdisaksophaCHillisCIsayamaTLimWIorioACrowtherMMortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trialsJ Thromb Haemost201513112012202026356595
   PubMed Web of Science ®Google Scholar
• KearonCAklEAOrnelasJAntithrombotic therapy for VTE disease: CHEST guideline and expert panel reportChest2016149231533526867832
   PubMed Web of Science ®Google Scholar
• FascoMJPrincipeLMR- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the ratJ Biol Chem19822579489449017068669
   PubMed Web of Science ®Google Scholar
• AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiGOral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Suppl44S88S
   Web of Science ®Google Scholar
• AgenoWBüllerHRFalangaAManaging reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White PaperThromb Haemost201611661003101027488232
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMUpdated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationEuropace201517101467150726324838
   PubMed Web of Science ®Google Scholar
• WannLSCurtisABEllenbogenKA2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesJ Am Coll Cardiol201157111330133721324629
   PubMed Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjectsCirculation2011124141573157921900088
   PubMed Web of Science ®Google Scholar
• LeviMMooreKTCastillejosCFComparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteersJ Thromb Haemost20141291428143624811969
   PubMed Web of Science ®Google Scholar
• ZahirHBrownKSVandellAGEdoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrateCirculation201513111829025403645
   PubMedGoogle Scholar
• NagallaSThomsonLOppongYBachmanBChervonevaIKraftWKReversibility of apixaban anticoagulation with a four-factor pro-thrombin complex concentrate in healthy volunteersClin Transl Sci20169317618027170068
   PubMed Web of Science ®Google Scholar
• DentaliFMarchesiCPierfranceschiMGSafety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysisThromb Haemost2011106342943821800002
   PubMed Web of Science ®Google Scholar
• AledortLMComparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activityJ Thromb Haemost20042101700170815456478
   PubMed Web of Science ®Google Scholar
• DibuJRWeimerJMAhrensCMannoEFronteraJAThe role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhageNeurocrit Care201624341341926545367
   PubMed Web of Science ®Google Scholar
• MarluRHodajEParisAAlbaladejoPCracowskiJLPernodGEffect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteersThromb Haemost2012108221722422627883
   PubMed Web of Science ®Google Scholar
• LeviMLevyJHAndersenHFTruloffDSafety of recombinant activated factor VII in randomized clinical trialsN Engl J Med2010363191791180021047223
   PubMed Web of Science ®Google Scholar
• WarkentinTEMargettsPConnollySJLamyARicciCEikelboomJWRecombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleedingBlood201211992172217422383791
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStahleHInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre studyClin Pharmacokinet20104925926820214409
   PubMed Web of Science ®Google Scholar
• ParasrampuriaDAMarburyTMatsushimaNPharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysisThromb Haemost2015113471972725566930
   PubMed Web of Science ®Google Scholar
• SchieleFvan RynJCanadaKA specific antidote for dabigatran: functional and structural characterizationBlood2013121183554356223476049
   PubMed Web of Science ®Google Scholar
• GlundSStangierJSchmohlMSafety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialLancet2015386999468069026088268
   PubMed Web of Science ®Google Scholar
• GlundSStangierJSchmohlMIdarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjectsBlood20141242134424914142
   PubMed Web of Science ®Google Scholar
• GlundSMoschettiVNorrisSA randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThromb Haemost2015113594395125789661
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med2015373651152026095746
   PubMed Web of Science ®Google Scholar
• PollackCVIdarucizumab for dabigatran reversal: updated results of the RE-VERSE AD StudyPresented at 2016 American Heart Association Scientific Sessions2016New Orleans, LA
   Google Scholar
• SiegalDMCurnutteJTConnollySJAndexanet alfa for the reversal of factor Xa inhibitor activityN Engl J Med2015373252413242426559317
   PubMed Web of Science ®Google Scholar
• HollenbachSLuGDeGuzmanFAbstract 14657: andexanet-alfa and PER977 (arapazine) correct blood loss in a rabbit liver laceration model-only andexanet reverses markers of fXa-mediated anticoagulationCirculation2014130Suppl 2A14657
   Google Scholar
• CrowtherMLevyGGLuGA phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitorsBlood2014124214269
   Web of Science ®Google Scholar
• ConnollySJMillingTJJrEiklboomJWthe ANNEXA-4 InvestigatorsAndexanet alfa for acute major bleeding associated with factor Xa InhibitorsN Engl J Med2016375121131114127573206
   PubMed Web of Science ®Google Scholar
• GreinacherAThieleTSellengKReversal of anticoagulants: an overview of current developmentsThromb Haemost2015113593194225832311
   PubMed Web of Science ®Google Scholar
• LaulichtBBakhruSLeeCSmall molecule antidote for anticoagulantsCirculation2012126suppl 21A11395
   Google Scholar
• AnsellJEBakhruSHLaulichtBEUse of PER977 to reverse the anticoagulant effect of edoxabanN Engl J Med2014371222141214225371966
   PubMed Web of Science ®Google Scholar
• Perosphere, IncStudy of PER977 administered to subjects with steady state edoxaban dosing and re-anticoagulation with edoxaban Available from: https://www.clinicaltrials.gov/ct2/show/NCT02207257. NLM identifier: NCT02207257Accessed April 3, 2017
   Google Scholar